Key papers in Hematology
Pofolia’s corpus holds 70 papers from the Hematology subfield (2012–2022). The list below starts with the most cited.
Most cited
Ranked by citation count. Because citations accumulate over time, this list naturally leans towards work published a few years ago; for where the field is now, see “recently added”.
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Blood · 2016 · Q1 · SJR 5.00 · FWCI 662.25 · 10,237 citations · Open access
The 2016 revision of the World Health Organization (WHO) classification for myeloid neoplasms and acute leukemia incorporates new biomarker data from gene expression analysis and next-generation sequencing.
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Blood · 2016 · Q1 · SJR 5.00 · FWCI 253.04 · 5,899 citations · Open access
Updated European LeukemiaNet (ELN) recommendations for adult acute myeloid leukemia (AML) diagnosis and management have been released, incorporating recent genomic discoveries and advances in minimal residual disease (MRD) detection.
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
Biology of Blood and Marrow Transplantation · 2014 · FWCI 204.80 · 5,418 citations · Open access
The 2014 NIH consensus refines diagnostic and staging criteria for chronic graft-versus-host disease (GVHD), maintaining the 2005 framework but improving specificity for prognosis, treatment guidance, and clinical trial eligibility.
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
New England Journal of Medicine · 2013 · Q1 · SJR 18.00 · FWCI 211.41 · 5,182 citations · Open access
Adult acute myeloid leukemia (AML) genomes are characterized by a low mutation burden, with an average of only 13 mutations per patient, of which 5 are recurrently mutated.
IL-6 in Inflammation, Immunity, and Disease
Cold Spring Harbor Perspectives in Biology · 2014 · Q1 · SJR 3.00 · 4,995 citations · Open access
Interleukin-6 (IL-6) is crucial for host defense against infection and injury, but its dysregulated synthesis drives chronic inflammation and autoimmunity.
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
American Journal of Nephrology · 2017 · Q1 · SJR 1.00 · FWCI 252.22 · 4,817 citations
Pharmacologic activation of hypoxia-inducible factors (HIFs) offers a novel approach to treating anemia in chronic kidney disease (CKD) by stimulating erythropoiesis through a transient pseudo-hypoxic state.
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
New England Journal of Medicine · 2014 · Q1 · SJR 18.00 · FWCI 129.16 · 4,781 citations · Open access
Somatic mutations in blood cells, termed age-related clonal hematopoiesis, are detectable in nearly 10-18% of individuals over 70 and are linked to significantly increased risks of hematologic cancer, all-cause mortality, and cardiovascular events.
Genomic Classification and Prognosis in Acute Myeloid Leukemia
New England Journal of Medicine · 2016 · Q1 · SJR 18.00 · FWCI 228.64 · 4,402 citations · Open access
A large-scale genomic analysis of 1540 acute myeloid leukemia (AML) patients has identified 11 distinct molecular subgroups, revealing that combinations of gene mutations, rather than single mutations, significantly impact disease progression and patient outcomes.
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Leukemia · 2022 · Q1 · SJR 3.00 · FWCI 509.65 · 3,967 citations · Open access
The 5th edition of the WHO Classification of Haematolymphoid Tumours refines diagnostic criteria for myeloid and histiocytic/dendritic neoplasms, emphasizing therapeutically actionable biomarkers and molecular biology.
Hematological Problems in Pediatric Intensive Care
Pediatric and adolescent medicine · 2013 · FWCI 457.10 · 3,517 citations
Desmopressin (DDAVP) has been a safe and cost-effective treatment for children with von Willebrand disease and Hemophilia A for nearly 35 years, significantly reducing exposure to plasma-derived products.
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
New England Journal of Medicine · 2014 · Q1 · SJR 18.00 · FWCI 113.48 · 3,516 citations · Open access
DNA sequencing readily detects clonal hematopoiesis with somatic mutations, a condition found in 10% of individuals over 65, significantly increasing their risk of developing hematologic cancers.
Acute Myeloid Leukemia
New England Journal of Medicine · 2015 · Q1 · SJR 18.00 · FWCI 117.54 · 3,393 citations
Recent biological discoveries in acute myeloid leukemia (AML) have deepened our understanding of its classification, though these insights have yet to significantly alter current treatment approaches.
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Blood · 2012 · Q1 · SJR 5.00 · FWCI 91.79 · 3,155 citations · Open access
A new prognostic model, the IPSS-R, has been developed using a larger dataset (n=7012) to more precisely predict outcomes for myelodysplastic syndromes (MDS) patients.
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Blood · 2022 · Q1 · SJR 5.00 · FWCI 386.60 · 3,068 citations · Open access
The European LeukemiaNet (ELN) has updated its 2022 recommendations for diagnosing and managing adult acute myeloid leukemia (AML), incorporating recent advances in molecular pathogenesis, genomic diagnostics, and novel therapies.
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 164.38 · 2,803 citations · Open access
Adding venetoclax to azacitidine significantly improved survival and remission rates in older or co-morbid patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood · 2022 · Q1 · SJR 5.00 · FWCI 345.64 · 2,739 citations · Open access
A new International Consensus Classification (ICC) for myeloid neoplasms and acute leukemias has been developed, integrating morphologic, clinical, and genomic data to define distinct disease entities.
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
New England Journal of Medicine · 2017 · Q1 · SJR 18.00 · FWCI 117.69 · 2,639 citations
Clonal hematopoiesis of indeterminate potential (CHIP), a common condition in older adults, is linked to a nearly doubled risk of coronary heart disease in humans and accelerated atherosclerosis in mice.
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
New England Journal of Medicine · 2017 · Q1 · SJR 18.00 · FWCI 128.48 · 2,209 citations · Open access
Adding the kinase inhibitor midostaurin to standard chemotherapy significantly improved overall survival for patients with acute myeloid leukemia (AML) and a FLT3 mutation.
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Journal of Clinical Oncology · 2015 · Q1 · SJR 4.00 · FWCI 73.19 · 2,189 citations · Open access
A new Revised International Staging System (R-ISS) for multiple myeloma effectively stratifies patients into three risk groups based on existing ISS staging, chromosomal abnormalities, and lactate dehydrogenase levels.
Genomewide Association Study of Severe Covid-19 with Respiratory Failure
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 211.29 · 2,175 citations
A genome-wide association study identified a genetic locus in the 3p21.31 gene cluster strongly associated with severe COVID-19 leading to respiratory failure.
Recently added
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Blood · 2022 · Q1 · SJR 5.00 · FWCI 386.60 · 3,068 citations · Open access
The European LeukemiaNet (ELN) has updated its 2022 recommendations for diagnosing and managing adult acute myeloid leukemia (AML), incorporating recent advances in molecular pathogenesis, genomic diagnostics, and novel therapies.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood · 2022 · Q1 · SJR 5.00 · FWCI 345.64 · 2,739 citations · Open access
A new International Consensus Classification (ICC) for myeloid neoplasms and acute leukemias has been developed, integrating morphologic, clinical, and genomic data to define distinct disease entities.
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Leukemia · 2022 · Q1 · SJR 3.00 · FWCI 509.65 · 3,967 citations · Open access
The 5th edition of the WHO Classification of Haematolymphoid Tumours refines diagnostic criteria for myeloid and histiocytic/dendritic neoplasms, emphasizing therapeutically actionable biomarkers and molecular biology.
Teclistamab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine · 2022 · Q1 · SJR 18.00 · FWCI 140.35 · 1,135 citations · Open access
Teclistamab, a bispecific antibody targeting CD3 and BCMA, achieved a 63.0% overall response rate in patients with relapsed/refractory multiple myeloma after a median of 5 prior therapies.
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
New England Journal of Medicine · 2020 · Q1 · SJR 18.00 · FWCI 164.38 · 2,803 citations · Open access
Adding venetoclax to azacitidine significantly improved survival and remission rates in older or co-morbid patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy.
Add this field to your daily feed
Pick your interests and new work in your area arrives every day, summarised. Full summaries live in the app.
Open the app